^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CLDN6-targeted CAR-T immunotherapy

    Related drugs:
    5ms
    CARVac: A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors (clinicaltrials.gov)
    P1, N=214, Recruiting, BioNTech Cell & Gene Therapies GmbH | N=147 --> 214 | Trial completion date: Jan 2040 --> Jan 2041 | Trial primary completion date: Jan 2027 --> Jan 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein) • CLDN6 (Claudin 6)
    |
    BNT211
    6ms
    AVENTURINE: A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm (clinicaltrials.gov)
    P2, N=0, Withdrawn, BioNTech SE | N=150 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    BNT211
    8ms
    AVENTURINE: A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, BioNTech SE
    New P2 trial
    |
    BNT211
    over1year
    Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and SWI/SNF gene alteration. (PubMed, Sci Rep)
    Furthermore, claudin-6 positive tumors have shown promising efficacy of CAR T cell therapy in the recently published BNT-211-01 trial (NCT04503278). This represents a personalized therapeutic option for this tumor subtype.
    Journal
    |
    CLDN6 (Claudin 6) • GPC3 (Glypican 3) • SALL4 (Spalt Like Transcription Factor 4)
    |
    BNT211
    almost2years
    CARVac: A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors (clinicaltrials.gov)
    P1, N=145, Recruiting, BioNTech Cell & Gene Therapies GmbH | Phase classification: P1/2 --> P1 | Trial completion date: Sep 2037 --> Jan 2040 | Trial primary completion date: Aug 2024 --> Jan 2027
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    AFP (Alpha-fetoprotein) • CLDN6 (Claudin 6)
    |
    CLDN6 expression • CLDN6 positive
    |
    BNT211
    almost2years
    CARVac: A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (clinicaltrials.gov)
    P1/2, N=114, Recruiting, BioNTech Cell & Gene Therapies GmbH
    Trial completion date • Trial primary completion date • Metastases
    |
    AFP (Alpha-fetoprotein) • CLDN6 (Claudin 6)
    |
    CLDN6 expression • CLDN6 positive
    |
    BNT211
    2years
    CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. (PubMed, Nat Med)
    A repeat of the dose escalation is ongoing and will identify a RP2D for pivotal trials. ClinicalTrials.gov Identifier: NCT04503278 .
    P1 data • Journal • CAR T-Cell Therapy
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    BNT211
    2years
    CARVac: A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (clinicaltrials.gov)
    P1/2, N=114, Recruiting, BioNTech Cell & Gene Therapies GmbH | Trial completion date: Sep 2036 --> Sep 2037 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    AFP (Alpha-fetoprotein) • CLDN6 (Claudin 6)
    |
    CLDN6 expression • CLDN6 positive
    |
    BNT211
    over2years
    The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis. (PubMed, J Transl Med)
    High expression of CLDN6 mRNA is associated with the dysregulation of distinct biological pathways regulating cell growth, proliferation, and cell-matrix interactions. Clinically, the expression of CLDN6 protein is a valuable adverse prognostic marker in EAC and GAC.
    Journal
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression • CLDN6 positive
    over2years
    BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-Amplifying RNA Vaccine (CARVac) (ESMO 2023)
    The safety profile in terms of CRS, ICANS and DLTs observed is in line with previously reported observations. We intend to present data on up to 42 pts, with a data cut-off of 10.09.2023.
    Late-breaking abstract • CAR T-Cell Therapy
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    BNT211
    over2years
    Advances of Claudin6-targeting drugs in cancer therapy (PubMed, Sheng Wu Gong Cheng Xue Bao)
    Many types of anticancer drugs targeting CLDN6 have been developed, including antibody-conjugated drugs (ADC), monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor T-cell immunotherapy (CAR-T). This paper briefly summarizes the structure, expression and function of CLDN6 in tumors, and reviews the current status and ideas of developing targeted CLDN6 anticancer drugs.
    Journal • IO biomarker
    |
    CLDN6 (Claudin 6)
    over2years
    CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product. (ASCO 2023)
    We intend to submit efficacy, safety and CAR T-cell pharmacokinetics data from 5 cohorts treated with 1x106, 1x107 or 1x108 CLDN6 CAR-T cells ± CARVac with a data cut-off of March 14th, 2023 from ≥17 treated patients as a late-breaking abstract. Clinical trial information: NCT04503278.
    P1 data • CAR T-Cell Therapy • IO biomarker
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    BNT211